Achille Fourtoy
Achille Fourtoy has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Annika Gerken
Fraunhofer Institute for Digital Medicine MEVIS, Max-von-Laue-Straße 2, 28359 Bremen, Germany
2 shared publications - Diego Valderrama
Department of Bioinformatics Fraunhofer Institute for Algorithms and Scientific Computing (SCAI) Sankt Augustin Germany
2 shared publications - Holger Fröhlich
Fraunhofer SCAI, Sankt Augustin, Germany
2 shared publications - India Mähler2 shared publications
- Sven Stodtmann
Clinical Pharmacology AbbVie Deutschland GmbH & Co. KG Ludwigshafen am Rhein Germany
2 shared publications
Latest Publications
- Open Access
- 20 November 2026
- Published by Elsevier in Journal of Biomedical Informatics
MultiNSDE: treatment-aware neural SDEs for generative modeling of real and counterfactual patient trajectories
- 20 November 2026
- Published by Elsevier in Journal of Biomedical Informatics
Open AccessMultiNSDE: treatment-aware neural SDEs for generative modeling of real and counterfactual patient trajectories
- Open Access
- 29 July 2026
- Published by Elsevier in SSRN Electronic Journal
MultiNSDE: Treatment-Aware Neural SDEs for Generative Modelingof Real and Counterfactual Patient Trajectories
Background: Synthetic patient data may facilitate biomedical research, trial planning, and the construction of synthetic control arms, but there is a lack of methods that enable the realistic generation of mixed-type longitudinal clinical trial data, specifically in the presence of treatment effects. Methods: We developed MultiNSDE, a neural stochastic differential equation framework for modeling high-dimensional static and longitudinal clinical study data, including continuous, categorical, and time-to-event outcomes. The model separates treatment- and placebo-associated dynamics, enabling individual trajectory simulation and counterfactual treatment assignment. Results: MultiNSDE was evaluated on three neurodegenerative disease trial datasets: A4 in Alzheimer’s disease, PRO-ACT in amyotrophic lateral sclerosis, and DATATOP in Parkinson’s disease. The model reproduced static and longitudinal data distributions, extrapolated clinically plausible trajectories, and generated coherent counterfactual outcomes under treatment-to-placebo and placebo-to-treatment shifts. Synthetic data generated by MultiNSDE preserved average treatment effect estimates observed in the real datasets. Conclusions: MultiNSDE enables generation of realistic mixed-type longitudinal clinical trial data while preserving clinically meaningful treatment-effect structure. It may support disease modeling, counterfactual simulation, and synthetic control generation in neurodegenerative disease research.
- 29 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessMultiNSDE: Treatment-Aware Neural SDEs for Generative Modelingof Real and Counterfactual Patient Trajectories
Background: Synthetic patient data may facilitate biomedical research, trial planning, and the construction of synthetic control arms, but there is a lack of methods that enable the realistic generation of mixed-type longitudinal clinical trial data, specifically in the presence of treatment effects. Methods: We developed MultiNSDE, a neural stochastic differential equation framework for modeling high-dimensional static and longitudinal clinical study data, including continuous, categorical, and time-to-event outcomes. The model separates treatment- and placebo-associated dynamics, enabling individual trajectory simulation and counterfactual treatment assignment. Results: MultiNSDE was evaluated on three neurodegenerative disease trial datasets: A4 in Alzheimer’s disease, PRO-ACT in amyotrophic lateral sclerosis, and DATATOP in Parkinson’s disease. The model reproduced static and longitudinal data distributions, extrapolated clinically plausible trajectories, and generated coherent counterfactual outcomes under treatment-to-placebo and placebo-to-treatment shifts. Synthetic data generated by MultiNSDE preserved average treatment effect estimates observed in the real datasets. Conclusions: MultiNSDE enables generation of realistic mixed-type longitudinal clinical trial data while preserving clinically meaningful treatment-effect structure. It may support disease modeling, counterfactual simulation, and synthetic control generation in neurodegenerative disease research.